TP53 and lung carcinoma: The molecular mechanism of CAM is still unclear; however, it has been shown that CAM increases p53, FOXO3a and Ku70 acetylation level through SIRT1 and SIRT2 inhibition and consequently sensitizes cancer cells (e.g., NCI H460 lung cancer cells) to PAX, which is ordinarily also utilized likewise in TNBC therapy [17].